The Cost-Effectiveness of Anemia Treatment for Persons with Chronic Kidney Disease

• Published in: PloS one 2016-07, Vol.11 (7), p.e0157323-e0157323
• Main Authors: Yarnoff, Benjamin O, Hoerger, Thomas J, Simpson, Siobhan A, Pavkov, Meda E, Burrows, Nilka R, Shrestha, Sundar S, Williams, Desmond E, Zhuo, Xiaohui
• Format: Article
• Language: English
• Subjects: Adult; Age; Anemia; Anemia - blood; Anemia - complications; Anemia - therapy; Calibration; Care and treatment; Choirs; Chronic kidney failure; Complications and side effects; Cost analysis; Cost-Benefit Analysis; Demographic aspects; Diabetes; Dialysis; Dietary supplements; Disease control; Disease prevention; Economic aspects; Erythropoietin; Guidelines; Health policy; Heart attacks; Hemodialysis; Hemoglobin; Hemoglobins - metabolism; Humans; Iron; Kidney diseases; Kidneys; Medical treatment; Medicine and Health Sciences; Molecular Targeted Therapy - economics; Mortality; Nutrition; Prognosis; Quality of life; Quality-Adjusted Life Years; Renal Insufficiency, Chronic - complications; Social Sciences; Stroke
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0157323

Although major guidelines uniformly recommend iron supplementation and erythropoietin stimulating agents (ESAs) for managing chronic anemia in persons with chronic kidney disease (CKD), there are differences in the recommended hemoglobin (Hb) treatment target and no guidelines consider the costs or cost-effectiveness of treatment. In this study, we explored the most cost-effective Hb target for anemia treatment in persons with CKD stages 3-4. The CKD Health Policy Model was populated with a synthetic cohort of persons over age 30 with prevalent CKD stages 3-4 (i.e., not on dialysis) and anemia created from the 1999-2010 National Health and Nutrition Examination Survey. Incremental cost-effectiveness ratios (ICERs), computed as incremental cost divided by incremental quality adjusted life years (QALYs), were assessed for Hb targets of 10 g/dl to 13 g/dl at 0.5 g/dl increments. Targeting a Hb of 10 g/dl resulted in an ICER of $32,111 compared with no treatment and targeting a Hb of 10.5 g/dl resulted in an ICER of $32,475 compared with a Hb target of 10 g/dl. QALYs increased to 4.63 for a Hb target of 10 g/dl and to 4.75 for a target of 10.5 g/dl or 11 g/dl. Any treatment target above 11 g/dl increased medical costs and decreased QALYs. In persons over age 30 with CKD stages 3-4, anemia treatment is most cost-effective when targeting a Hb level of 10.5 g/dl. This study provides important information for framing guidelines related to treatment of anemia in persons with CKD.